HHS scraps 340B Drug Pricing Program Rebate Model Following Legal Challenges
A new court filing revealed Thursday that the Department of Health and Human Services (HHS) is abandoning its controversial rebate model for the 340B drug Pricing Program, a move met with widespread relief from hospitals. The proposed model, intended to increase clarity and prevent duplicate discounts, faced meaningful opposition due to concerns about administrative burdens and potential financial strain on healthcare providers.
The now-defunct model was scheduled to launch on January 1, 2024, but its implementation was blocked by courts citing both procedural and legal shortcomings. The decision to scrap the plan avoids a complex overhaul of the existing system and addresses mounting anxieties within the healthcare industry.
Established in 1992,the 340B program enables hospitals to purchase outpatient drugs at significantly reduced prices,with the stated goal of supporting care for low-income and uninsured patients. The scrapped rebate model would have shifted the discount structure, inviting pharmaceutical manufacturers to participate in a voluntary rebate system. Rather of receiving discounts upfront, providers would have been eligible for rebates after purchase, contingent upon submitting extensive data.
This shift, while aiming to address concerns about program integrity, was widely criticized for its potential to create significant financial hurdles. One healthcare advocate explained in November that the model would have created “difficult cash flow problems” for providers, particularly those specializing in expensive treatments. For example, Biktarvy, a widely used HIV medication costing approximately $4,200 per month, currently benefits from 340B discounts that reduce the price to around $2,100.the rebate model could have forced clinics to temporarily cover the full $4,200 cost while awaiting reimbursement.
These concerns fueled multiple lawsuits against HHS, most notably a December filing by the American Hospital Association (AHA) and a coalition of other hospital groups. The AHA argued that the rebate program would “undermine safety-net hospitals’ ability to offer more thorough care” and ultimately harm vulnerable communities.
“A rebate program that undermines safety-net hospitals’ ability to offer more comprehensive care would onyl harm the nation’s most vulnerable communities,” stated AHA CEO Rick Pollack.
the sentiment was echoed by other industry stakeholders. Tom Kraus, vice president of government relations at the American Society of health-System Pharmacists, lauded the decision, describing the rebate model as “unworkable and a threat to program integrity.” He further emphasized that rebates improperly shift costs from manufacturers to providers, contradicting the intent of Congressional legislation designed to secure manufacturer discounts.
Looking ahead, HHS has committed to issuing a new proclamation and soliciting public comments should it pursue further administrative reforms to the 340B program. This signals a willingness to engage with stakeholders and address concerns more collaboratively in the future.The agency’s decision to abandon the rebate model represents a significant victory for hospitals and a reprieve from a perhaps disruptive and costly overhaul of a vital program for vulnerable populations.
Why did HHS scrap the rebate model? The Department of Health and Human Services abandoned the plan following legal challenges that cited both procedural and legal shortcomings. Courts blocked the implementation, scheduled for January 1, 2024, due to these issues.
Who was involved? Key players
